10-Q: RetinalGenix Technologies Reports Increased Net Loss and Ongoing Going Concern Uncertainty in Q2 2024

RetinalGenix Technologies reported a significant increase in net loss for the second quarter of 2024 and continues to face substantial doubt about its ability to continue as a going concern.

Summary

• RetinalGenix Technologies reported a net loss of $2,809,509 for the six months ended June 30, 2024, compared to a net loss of $862,786 for the same period in 2023.
• The company's accumulated deficit reached approximately $13,919,000 as of June 30, 2024.
• Operating expenses increased significantly, driven by a large rise in stock-based compensation expenses.
• The company has minimal cash on hand, with $86,913 as of June 30, 2024, and is heavily reliant on related parties for financing.
• RetinalGenix is actively pursuing additional funding through investment bankers and individual investors, with a potential up-listing to the NASDAQ exchange.
• The company anticipates needing $12,200,000 to complete product development and achieve regulatory approvals.
• There is substantial doubt about the company's ability to continue as a going concern due to its ongoing losses and dependence on external funding.

Sentiment

Score: 2

Explanation: The document paints a very negative picture due to the significant increase in net loss, the company's weak cash position, the material weakness in internal controls, and the substantial doubt about its ability to continue as a going concern. The high stock-based compensation and reliance on related-party funding further contribute to the negative sentiment.

Positives

• The company is actively pursuing additional funding and a potential NASDAQ up-listing.
• The company is making progress in its planning to conduct pharmaceutical clinical studies for its medications.
• The company has engaged with Pearl IRB to conduct a study to personalize medical evaluations for patients receiving treatment for wet macular degeneration.
• The company has made advancements in its medical device development, including the RetinalCam and Retinal Imaging Screening Device.

Negatives

• The company has incurred significant net losses since inception and has an accumulated deficit of approximately $13,919,000.
• The company has minimal cash and is heavily reliant on related parties for financing.
• The company's operating losses and negative cash flows are expected to continue for at least the next several years.
• The company has a material weakness in internal control over financial reporting.
• The company has not generated any revenue since its inception.
• The company's auditors have expressed substantial doubt about its ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is in substantial doubt due to its ongoing losses and dependence on external funding.
• The company may not be able to secure additional financing when needed or on favorable terms.
• Failure to raise capital could force the company to delay, limit, reduce, or terminate product development.
• The company's internal controls over financial reporting are ineffective due to a material weakness.
• The company has not generated any revenue and may not become profitable.
• The company is subject to risks inherent in the establishment of a new business enterprise.

Future Outlook

The company anticipates needing $12,200,000 to complete product development and achieve regulatory approvals, and expects to finance its cash needs through public or private equity offerings, debt financings, strategic partnerships, collaborations and licensing arrangements or other capital sources.

Management Comments

• Management has concluded that our disclosure controls and procedures were ineffective as of June 30, 2024 due to a material weakness in our internal controls.
• Management is actively engaged in the planning for, and implementation of, remediation efforts to address our material weakness and improve our internal control over financial reporting and disclosure controls and procedures.

Industry Context

The company is operating in the ophthalmic research and development sector, focusing on technologies to diagnose and treat eye disorders. The company's focus on diabetic retinopathy and maculopathy aligns with the growing need for solutions in these areas. The company's strategy of combining retinal imaging with genetic mapping is a novel approach that could provide a competitive advantage.

Comparison to Industry Standards

• RetinalGenix's financial performance is significantly weaker than many established medical device companies, which typically have revenue streams and positive cash flows.
• Companies like Alcon and Bausch + Lomb, which are major players in the ophthalmic space, have substantial revenue and established product portfolios, unlike RetinalGenix which is still in the development phase.
• The high stock-based compensation expense relative to the company's size and stage of development is unusual compared to industry norms, where such expenses are typically tied to revenue generation and profitability.
• The company's reliance on related-party funding is also not typical for companies at this stage, as most seek external funding from venture capital or public markets.
• The lack of revenue and the substantial doubt about the company's ability to continue as a going concern are significant red flags compared to industry standards for companies seeking to commercialize medical devices.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings and is not aware of any pending or threatened legal proceeding against it that could have a material adverse effect on its business.

Related Party Transactions

• Sanovas has paid a significant portion of the company's operating expenses through June 2024 and was owed approximately $430,000 as of June 30, 2024.
• The company has received advances from related parties totaling $543,061 as of June 30, 2024.
• The company has a sublicense agreement with Sanovas Ophthalmology, requiring royalty payments upon commercial sales.
• The company allocated costs from Sanovas for services performed on its behalf.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and the substantial doubt about its ability to continue as a going concern.
• Employees may be impacted by potential delays or terminations of product development and commercialization efforts.
• Customers may face uncertainty regarding the availability of the company's products.
• Suppliers and creditors face increased risk due to the company's financial difficulties.
• The company's reliance on related parties for funding may create conflicts of interest.

Next Steps

• The company will continue to pursue additional funding through investment bankers and individual investors.
• The company will continue to develop its products and seek regulatory approvals.
• The company will implement remediation measures to address the material weakness in internal control over financial reporting.
• The company will continue to plan and conduct pharmaceutical clinical studies for its medications.

Key Dates

Keywords

RetinalGenix, Ophthalmic, Medical Devices, Financial Results, Going Concern, Net Loss, Stock-Based Compensation, Capital Raise, Internal Control, Research and Development